Avadel Pharmaceuticals (AVDL) Gains from Investment Securities (2016 - 2022)
Historic Gains from Investment Securities for Avadel Pharmaceuticals (AVDL) over the last 11 years, with Q4 2022 value amounting to $3.3 million.
- Avadel Pharmaceuticals' Gains from Investment Securities rose 4071250.0% to $3.3 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$29.1 million, marking a year-over-year decrease of 3833421.05%. This contributed to the annual value of -$29.1 million for FY2022, which is 3833421.05% down from last year.
- Per Avadel Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $3.3 million for Q4 2022, which was up 4071250.0% from -$18.2 million recorded in Q3 2022.
- In the past 5 years, Avadel Pharmaceuticals' Gains from Investment Securities ranged from a high of $3.3 million in Q4 2022 and a low of -$18.2 million during Q3 2022
- Over the past 5 years, Avadel Pharmaceuticals' median Gains from Investment Securities value was $8000.0 (recorded in 2021), while the average stood at -$2.7 million.
- Examining YoY changes over the last 5 years, Avadel Pharmaceuticals' Gains from Investment Securities showed a top increase of 4071250.0% in 2022 and a maximum decrease of 20147142.86% in 2022.
- Over the past 5 years, Avadel Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $776000.0 in 2018, then decreased by 20.36% to $618000.0 in 2019, then plummeted by 85.92% to $87000.0 in 2020, then plummeted by 90.8% to $8000.0 in 2021, then surged by 40712.5% to $3.3 million in 2022.
- Its Gains from Investment Securities was $3.3 million in Q4 2022, compared to -$18.2 million in Q3 2022 and -$14.1 million in Q2 2022.